Mar 04, 2024 7:03am EST Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients
Feb 14, 2024 7:03am EST Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting
Jan 29, 2024 7:03am EST Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference
Jan 23, 2024 7:03am EST Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones
Dec 18, 2023 7:03am EST Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on Dialysis
Nov 29, 2023 7:03am EST Unicycive Therapeutics to Participate in Two Investor Conferences in December 2023
Nov 14, 2023 4:15pm EST Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update
Oct 23, 2023 7:03am EDT Unicycive Therapeutics Reaches Alignment with the FDA on Path to File New Drug Application for Oxylanthanum Carbonate (OLC)
Sep 06, 2023 7:03am EDT Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD
